KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Operating Expenses (2016 - 2025)

Arbutus Biopharma (ABUS) has disclosed Operating Expenses for 13 consecutive years, with $6.3 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 59.11% to $6.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $52.2 million through Dec 2025, down 36.67% year-over-year, with the annual reading at $52.2 million for FY2025, 36.67% down from the prior year.
  • Operating Expenses hit $6.3 million in Q4 2025 for Arbutus Biopharma, down from $9.2 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $28.8 million in Q4 2022 to a low of $6.3 million in Q4 2025.
  • Historically, Operating Expenses has averaged $21.0 million across 5 years, with a median of $23.0 million in 2023.
  • Biggest five-year swings in Operating Expenses: surged 43.1% in 2021 and later crashed 60.31% in 2025.
  • Year by year, Operating Expenses stood at $24.0 million in 2021, then grew by 20.02% to $28.8 million in 2022, then decreased by 20.53% to $22.9 million in 2023, then plummeted by 32.26% to $15.5 million in 2024, then plummeted by 59.11% to $6.3 million in 2025.
  • Business Quant data shows Operating Expenses for ABUS at $6.3 million in Q4 2025, $9.2 million in Q3 2025, and $9.3 million in Q2 2025.